Physician profile
Elisha Ward
NPI 1356516587
$1,732.49
in general payments reported to CMS, 2019-2025
19 companies · $743 in 2025
The $743 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.11 · 2022: $154 · 2023: $421 · 2024: $393 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.86 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $601.21 | 2022-2025 | Sotyktu |
| Abbvie INC. | $335.34 | 2024-2025 | |
| Amgen INC. | $225.06 | 2024-2025 | Otezla, Otezla, Repatha |
| Arcutis Biotherapeutics, INC. | $113.82 | 2025 | Zoryve |
| Genzyme Corporation | $100.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.65 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $44.13 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $41.22 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $37.53 | 2023 | Trintellix |
| Ucb, INC. | $27.54 | 2023 | Cimzia |
| Janssen Pharmaceuticals, INC | $22.11 | 2021 | |
| Fresenius Kabi USA, LLC | $21.72 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $21.05 | 2025 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.83 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $17.44 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $15.27 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.12 | 2024 | Xifaxan |
| Lilly USA, LLC | $14.11 | 2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisha Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.